Ribociclib 200Mg Oral Tablet

DRUG3 trials

Conditions

Breast Cancer FemaleBreast Cancer Stage IBreast Cancer Stage IICYP3A4*22ER+ Breast CancerLocally Advanced Breast Cancer (LABC)Metastatic Breast Cancer

Phase 1

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

RecruitingNCT07002177

Forward Pharmaceuticals Co., Ltd.Breast Cancer Stage I, Breast Cancer Stage II, ER+ Breast Cancer +2

Start: 2025-06-01End: 2028-11-01Target: 196Updated: 2026-01-07

Phase 3

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruitingNCT04055493

Women's Cancer Study Group GmbHBreast Cancer Female

Start: 2019-07-02End: 2027-07-31Updated: 2026-10-09

Phase 4

Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype

WithdrawnNCT05691400

University of Michigan Rogel Cancer CenterCYP3A4*22

Start: 2024-03-31End: 2027-03-31Updated: 2024-02-02

Onkologische Welt2025-08-01

Clinicopathological Characteristics of a Distinct Tumor Phenotype: Invasive Lobular Carcinoma With Tubular Elements in the West German Study Group ADAPTcycle Trial

Laboratory Investigation2025-03-052 citations

Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study

JMIR Cardio2023-09-113 citations

Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer: ADAPTcycle.

Journal of Clinical Oncology2022-06-014 citations

ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).

Journal of Clinical Oncology2020-05-2018 citations

Ribociclib 200Mg Oral Tablet

Sponsors

Conditions

Phase 1

Phase 3

Phase 4

Related Papers